CAAS Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

CAAS Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-994	Closed	-$628K	–	884
2021 Q4	$628K	Hold	994	–	–	0.02%	508
2021 Q3	$602K	Hold	994	–	–	0.01%	581
2021 Q2	$555K	Sell	994 -3,526	-78%	-$1.79M	0.01%	710
2021 Q1	$2.14M	Buy	4,520 +4,500	+22,500%	+$2.19M	0.02%	579
2020 Q4	$10K	Buy	+20	New	+$10.8K	﹤0.01%	812
2020 Q3	–	Sell	-700	Closed	-$424K	–	583
2020 Q2	$437K	Buy	+700	New	+$397K	0.01%	325

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAAS Capital Management's REGN Position: Q1 2022 in Review

CAAS Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 994 shares — an estimated $628K sold.

CAAS Capital Management first reported a position in REGN in Q2 2020 and held it in 6 quarters. The position peaked at $2.14M in Q1 2021. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

CAAS Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
CAAS Capital Management sold 994 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $628K.
CAAS Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 6 quarters.
CAAS Capital Management's Regeneron Pharmaceuticals position peaked at $2.14M in Q1 2021.
1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.